Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Vaccine

• Publication date

  2001-06-14

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0264-410X(01)00090-1PMID 11395213
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens.

  2001cited by this paper
• DNA vaccination of mice against rabies virus: effects of the route of vaccination and the adjuvant monophosphoryl lipid A (MPL).

  2000cited by this paper
• Adjuvants for plasmid DNA vaccines.

  2000cited by this paper
• Sodium phosphate enhances plasmid DNA expression in vivo

  2000cited by this paper
• Enhanced type I immune response to a hepatitis B DNA vaccine by formulation with calcium- or aluminum phosphate.

  2000cited by this paper
• HIV-1 DNA vaccines and chemokines.

  1999cited by this paper
• Genes That Induce Immunity—DNA Vaccines

  1999cited by this paper
• Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously.

  1999cited by this paper
• IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile.

  1999cited by this paper
• Enhancement of DNA vaccine potency using conventional aluminum adjuvants.

  1999cited by this paper
• Effects of bacterial DNA on cytokine production by (NZB/NZW)F1 mice.

  1998cited by this paper
• Give us this day our daily germs.

  1998cited by this paper
• CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry.

  1998cited by this paper
• Give us this day our daily germs.

  1998cited by this paper
• Out on the farm with DNA vaccines

  1998cited by this paper
• Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.

  1998cited by this paper
• Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction

  1998cited by this paper
• First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response.

  1998cited by this paper
• Modulation of amplitude and direction of in vivo immune responses by co‐administration of cytokine gene expression cassettes with DNA immunogens

  1998cited by this paper
• DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans.

  1998cited by this paper
• Induction of Systemic and Mucosal Immune Responses to Human Immunodeficiency Virus Type 1 by a DNA Vaccine Formulated with QS-21 Saponin Adjuvant via Intramuscular and Intranasal Routes

  1998cited by this paper
• Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients.

  1998cited by this paper
• The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA.

  1997cited by this paper
• Spatial–temporal patterns of gene expression in mouse skeletal muscle after injection of lacZ plasmid DNA

  1997cited by this paper
• Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes.

  1997cited by this paper
• Cationic Liposomes Are a Strong Adjuvant for a DNA Vaccine of Human Immunodeficiency Virus Type 1

  1997cited by this paper
• DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction

  1997cited by this paper
• HIV‐1‐specific cell‐mediated immune responses induced by DNA vaccination were enhanced by mannan‐coated liposomes and inhibited by anti‐interferon‐γ antibody

  1997cited by this paper
• DNA vaccines.

  1997cited by this paper
• Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1

  1997cited by this paper
• Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes

  1997cited by this paper
• CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma.

  1996cited by this paper
• Immune activation by bacterial DNA: a new genetic code.

  1996cited by this paper
• Selected strategies to augment polynucleotide immunization.

  1996cited by this paper
• Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization.

  1996cited by this paper
• An Improved Plasmid DNA Expression Vector for Direct Injection into Skeletal Muscle

  1996cited by this paper
• Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway.

  1996cited by this paper
• A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung.

  1996cited by this paper
• The expanding universe of T-cell subsets: Th1, Th2 and more.

  1996cited by this paper
• Morphological observations on the fate of liposomes in the regional lymph nodes after footpad injection into rats.

  1996cited by this paper
• CpG motifs in bacterial DNA trigger direct B-cell activation

  1995cited by this paper
• Bone marrow is a major site of long-term antibody production after acute viral infection

  1995cited by this paper
• Cancer Gene Therapy Using Plasmid DNA: Purification of DNA for Human Clinical Trials

  1995cited by this paper
• Cancer Gene Therapy Using Plasmid DNA: Safety Evaluation in Rodents and Non-Human Primates

  1995cited by this paper
• Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein.

  1994cited by this paper
• Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against the hepatitis B virus surface antigen.

  1994cited by this paper
• Interleukin-6 is required in vivo for the regulation of stem cells and committed progenitors of the hematopoietic system.

  1994cited by this paper
• Heterologous protection against influenza by injection of DNA encoding a viral protein.

  1993cited by this paper
• Bovine herpesvirus 1: immune responses in mice and cattle injected with plasmid DNA

  1993cited by this paper
• Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans.

  1993cited by this paper
• Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma

  1993cited by this paper
• Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA.

  1991cited by this paper
• Interleukin-6: an overview.

  1990cited by this paper
• Direct gene transfer into mouse muscle in vivo.

  1990cited by this paper
• Current concepts of B cell modulation.

  1989cited by this paper
• B cell growth and differentiation activity of interleukin‐hp1 and related murine plasmacytoma growth factors. synergy with interleukin 1

  1988cited by this paper
• Characterization of a carcinogen‐induced murine B lymphocyte cell line of C3H/eB origin

  1977cited by this paper

• Live Attenuated Bacterial Vectors as Vehicles for DNA Vaccine Delivery: A Mini Review

  2024cites this paper
• Research Progress on Liposome Pulmonary Delivery of Mycobacterium tuberculosis Nucleic Acid Vaccine and Its Mechanism of Action

  2024cites this paper
• Meeting vaccine formulation challenges in an emergency setting: towards the development of accessible vaccines.

  2023cites this paper
• Non-viral COVID-19 vaccine delivery systems

  2020cites this paper
• Future Approaches to DNA Vaccination Against Hemorrhagic Fever Viruses.

  2018cites this paper
• Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity

  2017cites this paper
• Effective usage of cationic derivatives of polyprenols as carriers of DNA vaccines against influenza virus

  2017cites this paper
• A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells.

  2015cites this paper
• Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine-platforms for the battle against infectious diseases

  2015influential citation
• Nucleic acid (DNA) immunization as a platform for dengue vaccine development.

  2015cites this paper
• DNA Vaccines: How Much Have We Accomplished In The Last 25 Years?

  2015cites this paper
• Combination of MIDGE-Th1 DNA vaccines with the cationic lipid SAINT-18: studies on formulation, biodistribution and vector clearance.

  2014cites this paper
• Macaques against Measles Virus Protects Juvenile and Infant Rhesus Hemagglutinin and Fusion Proteins Vaccine Encoding the Measles Virus Use of Vaxfectin Adjuvant with DNA

  2014cites this paper
• Nucleic Acid Vaccines

  2013cites this paper
• Vaccination with Vaxfectin® adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia

  2013cites this paper
• A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes.

  2012cites this paper
• Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus

  2012cites this paper
• Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine.

  2012cites this paper
• Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection.

  2012cites this paper
• Nonclinical biodistribution, integration, and toxicology evaluations of an H5N1 pandemic influenza plasmid DNA vaccine formulated with Vaxfectin®.

  2011cites this paper
• DNA vaccines: an historical perspective and view to the future

  2011cites this paper
• Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target

  2010cites this paper
• Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses

  2010cites this paper
• Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.

  2010cites this paper
• Development of an Adjuvanted Plasmid DNA HSV-2 Vaccine for Prophylactic and Therapeutic Applications

  2010cites this paper
• Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines

  2010influential citation
• A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine.

  2009cites this paper
• Analysis of biomarkers after intramuscular injection of Vaxfectin-formulated hCMV gB plasmid DNA.

  2009cites this paper
• Vaxfectin, a cationic lipid-based adjuvant for protein-based influenza vaccines.

  2009cites this paper
• RAPID DEVELOPMENT OF A VAXFECTIN®-ADJUVANTED DNA VACCINE ENCODING PANDEMIC SWINE-ORIGIN INFLUENZA A VIRUS (H1N1) HEMAGGLUTININ

  2009cites this paper
• Vaxfectin-adjuvanted seasonal influenza protein vaccine: correlation of systemic and local immunological markers with formulation parameters.

  2009cites this paper
• Measles vaccines.

  2008cites this paper
• Use of Vaxfectin Adjuvant with DNA Vaccine Encoding the Measles Virus Hemagglutinin and Fusion Proteins Protects Juvenile and Infant Rhesus Macaques against Measles Virus

  2008influential citation
• Genetic Vaccines and Therapy

  2008cites this paper
• Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus.

  2008cites this paper
• A vaccine to prevent transmission of human malaria: A long way to travel on a dusty and often bumpy road

  2007cites this paper
• Evaluation of the antitumoral effect mediated by IL-12 and HSV-tk genes when delivered by a novel lipid-based system.

  2007cites this paper
• Vaxfectin™-Formulated Influenza DNA Vaccines Encoding NP and M2 Viral Proteins Protect Mice against Lethal Viral Challenge

  2007cites this paper
• Vaxfectin enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines.

  2006cites this paper
• Plasmid vaccines and therapeutics: from design to applications.

  2005cites this paper
• Vaccination with the recombinant allergen ProDer p 1 complexed with the cationic lipid DiC14-amidine prevents allergic responses to house dust mite.

  2005cites this paper
• Development of anthrax DNA vaccines.

  2004cites this paper
• Combined DNA Vaccines Formulated in DDA Enhance Protective Immunity against Tuberculosis

  2004cites this paper
• Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection

  2004cites this paper
• A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.

  2004cites this paper
• DNA vaccination: an update.

  2003cites this paper
• Absence of immunoglobulin E synthesis and airway eosinophilia by vaccination with plasmid DNA encoding ProDer p 1

  2003cites this paper
• Genetic Vaccines and Therapy

  2003cites this paper
• Enhancing Effect of Vaxfectin on the Ability of a Japanese Encephalitis DNA Vaccine to Induce Neutralizing Antibody in Mice

  2003influential citation
• The Use of DNA Vaccines for Neonatal/Early Life Childhood Immunization

  2003cites this paper
• Improved cellular and humoral immune responses against Mycobacterium tuberculosis antigens after intramuscular DNA immunisation combined with muscle electroporation.

  2002cites this paper
• Synergy between cationic lipid and co-lipid determines the macroscopic structure and transfection activity of lipoplexes.

  2002cites this paper
• Biochemical and biophysical characteristics of lipoplexes pertinent to solid tumour gene therapy.

  2002cites this paper
• Immunostimulatory activity of cationic-lipid-nucleic-acid complexes against cancer

  2002cites this paper
• Improved Tuberculosis DNA Vaccines by Formulation in Cationic Lipids

  2002cites this paper
• Plasmid Dna–based Vaccines Protect Mice and Ferrets against Lethal Challenge with A/vietnam/ 1203/04 (h5n1) Influenza Virus Plasmid Dna (pdna) Vaccines Represent an Alternative to Conventional Inactivated Influenza Vaccines That Are Likely to Experience Supply Constraints during a Pandemic. Several

  year unknowncites this paper